MX2021005018A - Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma. - Google Patents
Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma.Info
- Publication number
- MX2021005018A MX2021005018A MX2021005018A MX2021005018A MX2021005018A MX 2021005018 A MX2021005018 A MX 2021005018A MX 2021005018 A MX2021005018 A MX 2021005018A MX 2021005018 A MX2021005018 A MX 2021005018A MX 2021005018 A MX2021005018 A MX 2021005018A
- Authority
- MX
- Mexico
- Prior art keywords
- tgf
- pharmaceutical composition
- fusion protein
- receptor fusion
- protein pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente descripción se describen una composición farmacéutica de proteína de fusión del receptor TGF-ß y un uso de la misma. Específicamente, la composición farmacéutica comprende una proteína de fusión del receptor TGF-ß en un amortiguador de citrato de sodio, y la proteína de fusión del receptor TGF-ß comprende una porción dirigida al anticuerpo PD-L1 y una región extracelular TGF-ßRII. Además, la composición farmacéutica también puede comprender un azúcar y un tensioactivo no iónico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811328326 | 2018-11-09 | ||
PCT/CN2019/116593 WO2020094122A1 (zh) | 2018-11-09 | 2019-11-08 | 一种TGF-β受体融合蛋白药物组合物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021005018A true MX2021005018A (es) | 2021-06-15 |
Family
ID=70611696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021005018A MX2021005018A (es) | 2018-11-09 | 2019-11-08 | Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220017601A1 (es) |
EP (1) | EP3878461A4 (es) |
JP (1) | JP7436477B2 (es) |
KR (1) | KR20210090643A (es) |
CN (1) | CN112512550A (es) |
AU (1) | AU2019374363A1 (es) |
BR (1) | BR112021008288A2 (es) |
CA (1) | CA3118415A1 (es) |
MX (1) | MX2021005018A (es) |
TW (1) | TWI829799B (es) |
UA (1) | UA127771C2 (es) |
WO (1) | WO2020094122A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021078123A1 (en) | 2019-10-21 | 2021-04-29 | Nanjing Leads Biolabs Co., Ltd. | RECOMBINANT PROTEIN TARGETING PD-1 AND TGFβ |
CN113754777A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业(上海)股份有限公司 | 一种抗PD-L1/TGF-β融合蛋白 |
WO2022017487A1 (zh) * | 2020-07-24 | 2022-01-27 | 迈威(上海)生物科技股份有限公司 | TGF-β RII突变体及其融合蛋白 |
TW202214287A (zh) * | 2020-08-24 | 2022-04-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | TGF-β受體的融合蛋白與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途 |
WO2022042715A1 (zh) * | 2020-08-31 | 2022-03-03 | 杭州九源基因工程有限公司 | 靶向PD-L1和TGFβ的双功能融合蛋白及其制备方法与应用 |
CN114437204A (zh) * | 2020-10-30 | 2022-05-06 | 苏州盛迪亚生物医药有限公司 | 一种抗体或Fc融合蛋白的纯化方法 |
CN112940134B (zh) * | 2021-05-11 | 2021-09-03 | 正大天晴药业集团南京顺欣制药有限公司 | 针对PD-1和TGF-β的双功能蛋白 |
CN113289029B (zh) * | 2021-05-20 | 2023-09-05 | 上海赛金生物医药有限公司 | 一种单克隆抗体-细胞因子融合蛋白制剂 |
WO2023072043A1 (zh) * | 2021-10-26 | 2023-05-04 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物 |
CN116688115B (zh) * | 2022-03-18 | 2024-02-06 | 上海齐鲁制药研究中心有限公司 | 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4124815B2 (ja) | 1991-10-31 | 2008-07-23 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | TGF−β型受容体cDNAおよびその用途 |
DE69332026T2 (de) | 1992-10-29 | 2002-10-31 | Celtrix Pharma | Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel |
EP1846039A2 (en) | 2005-01-10 | 2007-10-24 | Research Development Foundation | Targeted chimeric molecules for cancer therapy |
CN100567325C (zh) * | 2006-03-31 | 2009-12-09 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用 |
WO2009152610A1 (en) | 2008-06-20 | 2009-12-23 | The Royal Institution For The Advancement Of Learning/Mcgill University | Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof |
BR122021025338B1 (pt) | 2009-11-24 | 2023-03-14 | Medimmune Limited | Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos |
EP2542590B2 (en) | 2010-03-05 | 2020-04-01 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
HUE051954T2 (hu) | 2011-11-28 | 2021-03-29 | Merck Patent Gmbh | ANTI-PD-L1 ellenanyagok és alkalmazásaik |
CN104334573A (zh) | 2012-04-30 | 2015-02-04 | 比奥孔有限公司 | 靶向/免疫调节性融合蛋白及其制造方法 |
NZ711445A (en) | 2013-03-12 | 2018-06-29 | Biocon Ltd | Fusion immunomodulatory proteins and methods for making same |
WO2015027082A1 (en) | 2013-08-22 | 2015-02-26 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
CA2931309C (en) | 2013-11-21 | 2022-06-21 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating pulmonary hypertension |
JP6731346B2 (ja) | 2014-02-10 | 2020-07-29 | メルク パテント ゲーエムベーハー | 標的TGFβ阻害 |
US20170190778A1 (en) * | 2014-05-27 | 2017-07-06 | Trustees Of Boston University | Inhibitors of fibroproliferative disorders and cancer |
WO2016036678A1 (en) * | 2014-09-02 | 2016-03-10 | Medimmune, Llc | Formulations of bispecific antibodies |
CN105435222B (zh) * | 2014-09-25 | 2018-05-29 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
EP3344660A4 (en) * | 2015-08-31 | 2019-07-03 | National Research Council of Canada | TGF-BETA-RECEPTOR-EKTODOMÄNENFUSIONSMOLEKÜLE AND USES THEREOF |
JP6983371B2 (ja) | 2015-11-17 | 2021-12-17 | スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド | 抗pd−l1抗体、その抗原結合フラグメントおよびその医療用途 |
WO2017134592A1 (en) * | 2016-02-03 | 2017-08-10 | Biocon Limited | Anti-cd20/immunomodulatory fusion proteins and methods for making same |
CN107513107B (zh) * | 2016-06-15 | 2022-03-15 | 上海南方模式生物科技股份有限公司 | 抗肿瘤融合蛋白及其制法和应用 |
WO2018129331A1 (en) * | 2017-01-07 | 2018-07-12 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted tgf-b inhibition |
KR102629503B1 (ko) | 2017-05-12 | 2024-01-24 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | TGF-β 수용체를 함유하는 융합 단백질 및 이의 약학적 용도 |
JP2023501971A (ja) * | 2019-11-01 | 2023-01-20 | アレス トレーディング ソシエテ アノニム | 癌の治療のための、放射線療法と共に用いるPD-1、TGFβ、及びATMの組み合わせ阻害 |
-
2019
- 2019-11-08 CA CA3118415A patent/CA3118415A1/en active Pending
- 2019-11-08 WO PCT/CN2019/116593 patent/WO2020094122A1/zh unknown
- 2019-11-08 MX MX2021005018A patent/MX2021005018A/es unknown
- 2019-11-08 AU AU2019374363A patent/AU2019374363A1/en active Pending
- 2019-11-08 JP JP2021523471A patent/JP7436477B2/ja active Active
- 2019-11-08 EP EP19882778.4A patent/EP3878461A4/en active Pending
- 2019-11-08 CN CN201980050112.9A patent/CN112512550A/zh active Pending
- 2019-11-08 BR BR112021008288-3A patent/BR112021008288A2/pt unknown
- 2019-11-08 TW TW108140652A patent/TWI829799B/zh active
- 2019-11-08 KR KR1020217016571A patent/KR20210090643A/ko active Search and Examination
- 2019-11-08 US US17/290,707 patent/US20220017601A1/en active Pending
- 2019-11-08 UA UAA202102928A patent/UA127771C2/uk unknown
Also Published As
Publication number | Publication date |
---|---|
EP3878461A4 (en) | 2022-08-17 |
JP7436477B2 (ja) | 2024-02-21 |
UA127771C2 (uk) | 2023-12-27 |
KR20210090643A (ko) | 2021-07-20 |
JP2022512862A (ja) | 2022-02-07 |
TW202031279A (zh) | 2020-09-01 |
CN112512550A (zh) | 2021-03-16 |
BR112021008288A2 (pt) | 2021-08-10 |
EP3878461A1 (en) | 2021-09-15 |
WO2020094122A1 (zh) | 2020-05-14 |
US20220017601A1 (en) | 2022-01-20 |
AU2019374363A1 (en) | 2021-06-03 |
TWI829799B (zh) | 2024-01-21 |
CA3118415A1 (en) | 2020-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021005018A (es) | Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma. | |
MX2019013023A (es) | Proteina de fusion con receptor tgf-?, y uso farmaceutico de la misma. | |
PH12019502123A1 (en) | Stable antibody formulation | |
PH12017500042A1 (en) | Interleukin-2/interleukin-2-receptor alpha fusion proteins and methods of use | |
MY195465A (en) | PD-L1 Antibody Pharmaceutical Composition and use Thereof | |
MX2019008413A (es) | Celulas pluripotentes inmunodiseñadas. | |
MX2018015271A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
MX2019005127A (es) | Poblaciones y productos de células madre mesenquimales y sus usos. | |
MX2021007368A (es) | Anticuerpos anti-receptor de transferrina y usos de los mismos. | |
MX2020005170A (es) | Formulaciones de proteinas de fusion vegfr-fc. | |
MX2018003306A (es) | Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina. | |
AU2018291128A1 (en) | Anti-B-cell maturation antigen chimeric antigen receptors with human domains | |
WO2018083087A3 (en) | Binding proteins | |
GEP20217249B (en) | Stable liquid pharmaceutical preparation | |
MY185802A (en) | Antibody formulation | |
PH12019501937A1 (en) | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | |
DK1856159T3 (da) | Kimære, rekombinante antigener af Toxoplasma gondii | |
EP3749683A4 (en) | FGF21 VARIANT, FUSION PROTEIN AND USE THEREOF | |
MX2020006822A (es) | Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa. | |
SG11202100989UA (en) | Novel fusion protein specific for cd137 and pd-l1 | |
MX2017003121A (es) | Formulaciones de anticuerpos. | |
ZA201908610B (en) | Il-15 protein complex pharmaceutical composition and uses thereof | |
MX2021003773A (es) | Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. | |
SG11202000115SA (en) | Novel therapeutic enzyme fusion protein and use thereof | |
EP4063385A4 (en) | GIPR ANTIBODY AND FUSION PROTEIN BETWEEN THE SAME AND GLP-1, AND PHARMACEUTICAL COMPOSITION AND ASSOCIATED APPLICATION |